‘Transformative’ cancer treatment: FDA approves gene therapy that functions as a ‘living drug’ – Los Angeles Times
Los Angeles Times |
‘Transformative’ cancer treatment: FDA approves gene therapy that functions as a ‘living drug’
Los Angeles Times In a step that heralds a new era in cancer treatment, the U.S. Food and Drug Administration said Wednesday it has approved a form of gene therapy that is highly effective at fighting an aggressive form of leukemia in young patients with no other options. FDA Approves First Gene Therapy For LeukemiaNPR Revolutionary gene therapy approved for leukemia — at $475000 price tagUSA TODAY FDA approval brings first gene therapy to the United StatesFDA.gov MIT Technology Review –ABC News –Science Magazine all 152 news articles » |
WABC-TV |
Breakthrough cancer treatment uses patient’s own blood cells to attack childhood leukemia
WABC-TV “This is a brand new way of treating cancer,” said Dr. Stephan Grupp of Children’s Hospital of Philadelphia, who treated the first child with CAR–T cell therapy – a girl who’d been near death but now is cancer-free for five years and counting. “That’s … |
|
FDA Approves Actemra for CAR T Cell-Induced CRS
PharmaLive (press release) (subscription) “Until today, there has never been an FDA-approved treatment to manage severe cytokine release syndrome associated with CAR T cell therapy, which is marked by a rapid onset and can cause life-threatening complications,” said Sandra Horning, M.D., chief … |
Medical Daily |
Stem Cell Graft Repairs Spinal Cord Injury, Helps Paralyzed Mice Move Again
Medical Daily Researchers were able to stimulate limb function in paralyzed mice by implanting human stem cells into their spinal cords. We’re not close to repeating the test in people, but the study shows it may be possible some day with further research. The … Human Stem Cells Repair Spinal Cord Injuries In Mice At Human Biological RateGears Of Biz |
|
New Incyte, Merck skin cancer immunotherapy study results disclosed, and they look promising
STAT pdated results were disclosed Wednesday night from a mid-stage clinical trial of Incyte’s epacadostat combined with Merck’s Keytruda to treat patients with metastatic melanoma. The new data, culled from the study Incyte calls ECHO-202, look good … |